Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer

Yoshiyuki Matsui, Boris A. Hadaschik, Ladan Fazli, Raymond J. Andersen, Martin E. Gleave and Alan I. So
Yoshiyuki Matsui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris A. Hadaschik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ladan Fazli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond J. Andersen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin E. Gleave
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan I. So
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-09-0148 Published August 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Hsp27 protein expression increases in bladder cancer tissue. A, immunohistochemical staining of Hsp27 in a human bladder cancer tissue microarray. Hsp27 levels were graded from 0 to +3 representing the range from no expression to high expression of Hsp27 by visual scoring. Four representative images show negative (0), low (1), moderate (2), and high (3) Hsp27 staining. B, immunostaining intensity of Hsp27 comparing normal bladder tissue (n = 5) and bladder cancer (n = 29). The grading score of Hsp27 expression from tissue microarray was calculated as mean ± SE and compared among normal bladder tissue and bladder cancer. C, immunostaining intensity of Hsp27 compared among normal bladder tissue, low-grade bladder cancer, and high-grade bladder cancer. The intensity was stratified into three groups consisting of negative, low to moderate, and high expression of Hsp27.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Suppression of Hsp27 protein enhances cytotoxicity in bladder cancer cells. A, sequence-specific suppression of Hsp27 protein levels by OGX427 in bladder cancer cells. Cells were treated with 50 nmol/L OGX427 or ScrB control oligodeoxynucleotide for 2 consecutive days; 72 h later, total protein was extracted and Hsp27 expression was analyzed by immunoblotting. B, flow cytometric analysis after treatment with OGX427and HTI-286. KU7-luc cells were treated with 50 nmol/L OGX427 or control oligodeoxynucleotide daily for 2 d. After 72 h of incubation with medium ± 0.6 nmol/L HTI-286, flow cytometry was used to quantify the percentage of cells in each cell cycle phase. *, P < 0.05. C, i, RT-PCR analysis showing MDR-1 expression in four different bladder cancer cell lines; ii, effects of OGX427 on HTI-286–induced cytotoxicity in bladder cancer cells. Cells were transfected with 50 nmol/L OGX427 or ScrB control oligodeoxynucleotide for 2 consecutive days and incubated with medium ± 0.5 nmol/L HTI-286 for 72 h. Cell viability was determined by MTS assays and is indicated by the ratio to cell viability when treated with drug vehicle only. *, P < 0.05. D, enhancement of various chemotherapeutic agents–induced cytotoxicity by OGX427 in KU7-luc cells. Cells were transfected with 50 nmol/L OGX427 or ScrB control oligodeoxynucleotide for 2 consecutive days and incubated with medium ± 20 nmol/L paclitaxel, 7.5 μmol/L cisplatinum (CDDP), or 10 nmol/L gemcitabine for 48 to 72 h. Cell viability was determined by MTS assays. *, P < 0.05.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Suppression of Hsp27 combined with chemotherapeutic agents inactivated Akt signaling and promoted apoptosis. A, Western blot analysis showing the effects of combination treatment with OGX427 and HTI-286 in KU7-luc cells. Cells were treated as described in Fig. 2B and then subjected to Western blot analysis. Black arrows, cleaved forms of caspase-9 and poly(ADP-ribose) polymerase (PARP). B, effects of p38 inhibition on the susceptibility to HTI-286 and OGX427 of KU7-luc cells. Cells were transfected with 50 nmol/L OGX427 or ScrB control oligodeoxynucleotide for 2 consecutive days and incubated with medium ± 0.5 nmol/L HTI-286 and/or 10 μmol/L SB203580 for 72 h and then subjected to Western blot analysis. C, Western blot analysis showing the effects of combination treatment with OGX427 and HTI-286 in KK47 cells. Cells were treated as described in Fig. 2B and then subjected to Western blot analysis. D, Western blot analysis showing the effects of combination treatment with OGX427 and various chemotherapeutic agents in KU7-luc cells. Cells were treated as described in Fig. 2D and then subjected to Western blot analysis.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Overexpression of Hsp27 protein contributes to chemoresistance against HTI-286 in bladder cancer cells. A, top, expression level of Hsp27 in lysates harvested from T24 cells infected with empty lentiviral vector (mock) or Hsp27-expressing lentiviral vector (Hsp27). T24 cells were infected with lentivirus as described in Materials and Methods, and their cell lysates were subjected to Western blot analysis. Bottom, effect of overexpression of Hsp27 protein on the susceptibility to HTI-286 in T24 cells. The results of MTS assays of T24 mock (open circles) and T24 Hsp27 (black squares) treated with HTI-286 at the indicated concentrations for 72 h are shown as average ± SE from three independent experiments. Cell viability is indicated as the ratio to cell viability with no treatment. *, P < 0.05. B, induction of Akt activation and reduced poly(ADP-ribose) polymerase cleavage after HTI-286 treatment by Hsp27 overexpression. Cells were treated by 1.0 nmol/L HTI-286 or DMSO for 72 h and then lysed in radioimmunoprecipitation assay buffer and subjected to Western blot analysis. C, effects of Akt inactivation on the susceptibility to HTI-286 of T24 mock cells and T24 Hsp27 cells. Cells were treated by 1.0 nmol/L HTI-286 (white column) or HTI-286 + 20 μmol/L LY294002 (black column) for 72 h. Cell viability was determined by MTS assays and is indicated by the ratio to cell viability when treated with drug vehicle only. *, P < 0.05.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Intravesical instillation of HTI-286 and OGX427 suppresses the in vivo tumor growth on orthotopic bladder cancer xenografts. A, 28 female nude mice were inoculated with 2 × 106 KU7-luc tumor cells on day 0 and randomized on day 5 to receive either treatment with ScrB + DMSO, ScrB + HTI-286, OGX427 + DMSO, or OGX427 + HTI-286. ScrB or OGX427 was administered three times a week, and HTI-286 or DMSO was administered biweekly for 2 consecutive weeks. Tumor growth was determined on days 5, 10, 15, 20, and 25 in a Xenogen IVIS200 camera. *, P < 0.05, Kruskal Wallis test; †, P < 0.05, between ScrB + HTI-286 and OGX427 + HTI-286 groups; §, P < 0.01, between OGX427 + DMSO and OGX427 + HTI-286 groups, Mann-Whitney U tests. B, representative sequences of bioluminescence images of mice from each treatment group taken on the day of randomization (day 5) and at days 15 and 25.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Intravesical instillation of HTI-286 and OGX427 suppresses the expression of Hsp27 and Akt activation on orthotopic bladder cancer xenografts. A, Western blot analysis showing representative Hsp27 or pAkt expression levels in mouse bladders. Protein was extracted from whole-bladder specimens of mice treated by indicated drugs and assessed by Western blot analysis. B, corresponding bladder immunohistochemistry of each treatment group. The bladders were removed on day 25, embedded in paraffin, and stained with H&E, Hsp27, and pAkt. Magnification, ×2.5 for H&E and ×10 for Hsp27 and pAkt on a BLISS workstation (Bacus Laboratories).

PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (8)
August 2009
Volume 8, Issue 8
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer
Yoshiyuki Matsui, Boris A. Hadaschik, Ladan Fazli, Raymond J. Andersen, Martin E. Gleave and Alan I. So
Mol Cancer Ther August 1 2009 (8) (8) 2402-2411; DOI: 10.1158/1535-7163.MCT-09-0148

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer
Yoshiyuki Matsui, Boris A. Hadaschik, Ladan Fazli, Raymond J. Andersen, Martin E. Gleave and Alan I. So
Mol Cancer Ther August 1 2009 (8) (8) 2402-2411; DOI: 10.1158/1535-7163.MCT-09-0148
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • A Novel TRAIL-Based Technology for Tumor Therapy
  • Trastuzumab Targeting of Metastatic Esophageal Cancer
  • Mcl-1 Determines the Fate of KSP-Inhibited Cells
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement